Product Images Lovastatin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Lovastatin NDC 10544-242 by Blenheim Pharmacal, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a description of Lovastatin, a drug used to lower cholesterol. The tablets come in 10mg strength and are packaged in a bottle containing 90 tablets. The NDC (National Drug Code) and MFG (Manufacturer) numbers are provided along with the lot number and expiration date. The tablets should be stored in a controlled room temperature, and kept out of the reach of children. Dosage should be as per the instructions provided with the package, and it is only available under prescription.*
This is a description for Lovastatin Tablets, USP 20mg. The package contains 30 tablets, and the NDC number is 1050424130. The tablets are manufactured by 6144214210, and the lot number is BPODOOOONS. The expiration date is not readable. Lovastatin is the active ingredient, and it is only available with a prescription. The tablets should be stored in a controlled room temperature, between 20°C and 25°C, and in a light-resistant container, away from children. There is no available information regarding the dosage, which can be found in the package insert.*
This is a description of a medication called Lovastatin Tablets, USP, with a dosage of 40mg per tablet. The package contains 30 tablets and is only available with a prescription. The medication should be stored in a temperature-controlled room, between 20°C and 35°C (68-77°F). Lovastatin is known to lower cholesterol levels; each tablet contains 40mg of the active ingredient. This medication was manufactured by Carisbad Technology Inc, and packaged by Blenheim Pharmacal. The label has different LOT numbers and expiration dates. The medication should be kept out of reach of children and should be protected from light.*
This appears to be a graph or chart related to the "Acute Major Coronary Events" and the proportion of participants without such an event. The graph is divided into five sections (labeled 1-4 and i) and there is a label for "Years of Follow-up" at the bottom. Without more context or information, it's difficult to provide a more detailed description or analysis.*
The text provides a list of drug interactions that are associated with an increased risk of myopathy/rhabdomyolysis, including prescribing recommendations for each drug. The drugs include strong CYP3A4 inhibitors such as ketoconazole, HIV protease inhibitors, boceprevir, telaprevic, nefazodone, cobicistat-containing products, gemfibrozil, cyclosporine, danazol, diltiazem, and dronedarone. The recommendations suggest avoiding certain drugs with lovastatin, limiting the daily intake of lovastatin to 20-40 mg, and avoiding grapefruit juice.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.